Application of new acute kidney injury biomarkers in human randomized controlled trials.
Ontology highlight
ABSTRACT: The use of novel biomarkers of acute kidney injury (AKI) in clinical trials may help evaluate treatments for AKI. Here we explore potential applications of biomarkers in simulated clinical trials of AKI using data from the TRIBE-AKI multicenter, prospective cohort study of patients undergoing cardiac surgery. First, in a hypothetical trial of an effective therapy at the time of acute tubular necrosis to prevent kidney injury progression, use of an indirect kidney injury marker such as creatinine compared to a new direct biomarker of kidney injury reduces the proportion of true acute tubular necrosis cases enrolled. The result is a lower observed relative risk reduction with the therapy, and lower statistical power to detect a therapy effect at a given sample size. Second, the addition of A
SUBMITTER: Parikh CR
PROVIDER: S-EPMC4869991 | biostudies-literature | 2016 Jun
REPOSITORIES: biostudies-literature
ACCESS DATA